fbpx

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

 

  • Eleven finalists have been selected from a strong roster of talent to compete at the inaugural Lyfebulb-Helsinn  Innovation Summit, March 26-27, Monaco
  • The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer supportive care using drugs, medical devices, consumer products, or healthcare information technologies
  • The award will be presented to the finalist demonstrating outstanding science and entrepreneurial potential to bring their ideas to the market

Lyfebulb-Helsinn Innovation Award & Summit

MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, March 1, 2018:

 

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. The finalists are invited to compete at the Lyfebulb-Helsinn Innovation Summit & Award, which will be hosted on 26-27 March 2018, by Lyfebulb and Helsinn at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco.

Due to the high quality and quantity of applications this year, there will be 11 finalists:

  • Samuel Wagner of Batu Biologics, Inc
  • Massimo Bocchi of Cellply Srl
  • Walid Al-Akkad of Engitix Ltd
  • Gitte Pedersen of Genomic Expression, Inc
  • Lorenzo Pradella of GreenBone Ortho srl
  • Samir Housri of Mednet, Inc
  • Till Erdmann of Myelo Therapeutics GmbH
  • Christian Apfel of SageMedic, Inc
  • Aaron Horowitz of Sproutel, Inc
  • Thierry Desjardins of Surgisafe Ltd
  • Boaz Gaon of Wisdo Ltd

The Award will recognize outstanding potential among entrepreneurs who have demonstrated an ability to develop and bring to the market innovation designed to improve the quality of life of people with cancer using drugs, medical devices, consumer products and healthcare information technologies. The finalists represent companies of all sizes that have been founded by cancer patients, cancer survivors, or those with close relatives with cancer.

The finalists were selected by Karin Hehenberger, MD PhD, CEO and Founder of Lyfebulb, Leslie Brille, Chief Investment Officer, Lyfebulb, Riccardo Braglia, Helsinn Group Vice Chairman and CEO and Roberto De Ponti, Head of Corporate New Ventures and Strategic Investments, Helsinn International Services. The Innovation Summit has been founded upon Lyfebulb’s concept of Patient Entrepreneurship and Helsinn’s determination to provide the best supportive care for cancer patients and to improve the health and quality of life of every person affected by cancer. A “pitch session” will be held at the summit, where a winner will be selected from the eleven finalists by a panel of experts.

“At Lyfebulb, we interact with numerous individuals who are using their own experiences with chronic disease to originate and develop effective solutions to help others. The level of innovation demonstrated by people who submitted their ideas to the first Lyfebulb-Helsinn Innovation Award were of a very high caliber and we commend all of them. Core to Lyfebulb’s Mission is to empower individuals living with chronic disease, and by embracing patient entrepreneurs and furthering their ideas and businesses, we are doing exactly that.” says Dr. Karin Hehenberger.

Riccardo Braglia added, “I know from experience how a cancer diagnosis can often be a spur towards greater dynamism and entrepreneurship and have seen many examples of great innovation from people who have first-hand experience with the disease. I am looking forward to learning more about the potential of their concepts and am confident that the expertise and industry experience of the judging panel will help choose a finalist who can innovate to improve the lives of people with cancer.”

About Lyfebulb

Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and Inflammatory Bowel Disease.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Helsinn International Services sarl

Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.  

About Helsinn Investment Fund S.A., SICAR

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.

For more information, visit www.helsinninvestmentfund.com

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

For more information:

Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.com and follow us on TwitterLinkedIn and Vimeo.

Press Contact for Lyfebulb:

Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb,
Phone: + 00 1 917-575-0210
karin@lyfebulb.com
www.lyfebulb.com
We are on Twitter. Follow us @Lyfebulb

A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award

The Award recognizes Patient Entrepreneurs’ Innovative Efforts and Ideas for cancer and cancer supportive care using drugs, medical devices, consumer products, or healthcare information technologies. Newly appointed jury panel members unveiled Deadline for submissions: January 22, 2018

MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, JANUARY, 9, 2018:Lyfebulb and Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, invite patient entrepreneurs that have embraced and endured the real life experiences of cancer to compete for the Lyfebulb-Helsinn Innovation Award. It has been announced today that:

  • Carolyn R. “Bo” Aldige, President and Founder of the Prevent Cancer Foundation
  • Stephen Squinto, PhD, Lyfebulb Chairman and Co-Founder, Venture Partner at Orbimed, and Co-Founder of Alexion
  • Professor Patrick Rampal, MD, President of the Scientific Center of Monaco
  • Professor Franco Cavalli, MD, Director of Oncology, Oncology Institute of Southern Switzerland
  • Professor Françoise Meunier, MD, EORTC Director Special Projects

are the newly-appointed jury panel members of the first Lyfebulb- Helsinn Innovation Award. The Award will recognize outstanding entrepreneurial potential to commercialize innovative efforts and ideas to better manage and improve the quality of life of cancer patients with respect, integrity, and quality, using drugs, medical devices, consumer products and healthcare information technologies. Established companies of all sizes founded by cancer patients, cancer survivors, or those having a close relative with cancer, who have created a product to address issues encountered by cancer patients, are invited to submit applications by January 22, 2018, through the Lyfebulb-Helsinn Innovation Summit & Award website, where more information regarding eligibility and key criteria can also be found.

Ten finalists will be selected by Karin Hehenberger, MD PhD, CEO and Founder of Lyfebulb, and Mr. Riccardo Braglia, Helsinn Group Vice Chairman and CEO, and invited to compete at the Innovation Summit which will be hosted on 26-27 March 2018, by Helsinn Investment Fund at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco. The Summit is founded upon Lyfebulb’s concept of Patient Entrepreneurship and Helsinn’s determination to provide the best supportive care for cancer patients and to improve the health and quality of life of every person affected by cancer. At the summit, the top finalists will be chosen by a panel of experts through a special “pitch session.” In recognition of the best innovative efforts and ideas, a symbolic monetary prize of USD 25’000 will be given to the entrepreneur winner to advance his/her business and use his/her life expertise to help manage the burden of cancer.

“At Lyfebulb, we come into contact with many people who are putting their own experiences with cancer towards developing solutions to help others. Now, for the first time, patient entrepreneurs have the opportunity to receive exposure and financing toward their companies through a targeted event to help them advance their cause,” says Dr. Karin Hehenberger.

Riccardo Braglia added, “Lyfebulb is about encouraging the best in patient entrepreneurship, drawing on the talents of people with first-hand experience of the cancer journey to help develop innovative approaches to cancer supportive care, and this is very much aligned with Helsinn’s journey. We are delighted of the jury panel – their expertise, experience, industry knowledge and dynamism in helping people with cancer will be invaluable.”

About Lyfebulb
Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and Inflammatory Bowel Disease.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Helsinn Investment Fund
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients. Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
For more information, visit www.helsinninvestmentfund.com

About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.

For more information:
Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication, Helsinn
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Info-hhc@helsinn.com
Please visit www.helsinn.com
We are on Twitter. Follow us @HelsinnGroup
We are on LinkedIn. Follow us @ Helsinn Group

Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb,
Phone: + 00 1 917-575-0210
Email: karin@lyfebulb.com
Please visit www.lyfebulb.com
We are on Twitter. Follow us @Lyfebulb

Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease

NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) — Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients, industry and investors to support user-driven innovation, is partnering with UnitedHealth Group (NYSE:UNH) to launch an innovation challenge featuring new businesses and products aimed at treating inflammatory bowel disease (IBD).

According to the Centers of Disease Control and Prevention, up to 1.3 million people in the United States are affected by IBD, which includes Crohn’s disease (CD) and ulcerative colitis (UC). Lyfebulb and UnitedHealth Group will help raise awareness for the conditions and stimulate user-driven innovation. By linking entrepreneurs with representatives from UnitedHealth Group and Lyfebulb, the partnership will spotlight the entrepreneurs’ efforts and ideas, and provide professional discussion, direction and inspiration.

The innovation challenge, to take place in the spring and summer of 2018, will be open to entrepreneurs living with IBD, or who have family members living with IBD, who have founded a company to develop an innovative idea for better management of IBD using pharmaceuticals, biotechnology, medical devices or consumer products. Eligibility criteria and official rules will be announced by Lyfebulb in April. UnitedHealth Group will host an innovation event in July for 10 finalists. A panel of judges will award cash prizes to three winners, to be used for their company’s further development of the winning innovations.

“Patients living with chronic disease and caregivers caring for someone with chronic disease understand the many challenges they face and are often in the best position to offer tangible solutions,” said Deneen Vojta, M.D., executive vice president, Research & Development, UnitedHealth Group. “UnitedHealth Group’s partnership with Lyfebulb will help place the patient at the center of early-stage innovation, thus providing us a unique opportunity to learn from and be inspired by patient-entrepreneurs.”

“This partnership with UnitedHealth Group in IBD means a tremendous amount to Lyfebulb in our efforts to enhance patient-driven innovation,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Continuing to build on the concept of patient entrepreneurs and partnering with leaders across health care are key components to fulfilling our mission to improve the quality of life of people living with chronic disease.”

Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD, CEO Lyfebulb, phone: 917-575-0210 email: karin@lyfebulb.com

About Lyfebulb
Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and IBD.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About UnitedHealth Group
UnitedHealth Group (NYSE:UNH) is a diversified health and well-being company dedicated to helping people live healthier lives and helping make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Press Contact for UnitedHealth Group:
Jim Merwin, Senior Director, ERD, phone: 952-936-6070, to email: james_merwin@uhg.com

Announcing the Lyfebulb-Novo Nordisk Innovation Award Winner!

The first Lyfebulb Novo-Nordisk Innovation Summit in Copenhagen, Denmark has wrapped! After a few jam-packed days that included dinners, workshops, speeches by Lyfebulb founder and CEO, Karin Hehenberger, and Novo Nordisk Senior Vice President, Device R&D, Kenneth Strømdahl, as well as pitches from each of our ten patient entrepreneur finalists, we have a WINNER!

Congratulations to Brianna Wolin, CEO and co-founder of Find Your Ditto, who received the first ever Lyfebulb-Novo Nordisk Innovation Award! Wolin’s company is a mobile platform for connecting individuals living with the same chronic illness locally for on-demand, in-person peer support.

b64a2226

“To be recognized by an innovative organization such as Lyfebulb and Novo Nordisk, a global pharmaceutical leader in diabetes care, is a true honor and an affirmation that our work to helping change the landscape surrounding isolation and depression in chronic illness communities is fully worthwhile,” said Brianna Wolin. “I’m so proud to have our mission – creating a world where no person living with a chronic illness ever has to feel alone – highlighted by this award.”

The competition was judged by five key opinion leaders and influences in the diabetes community, and Wolin was selected from a distinguished group of patient entrepreneur finalists that included:

  • Shilo Ben-Zeev, Smartzyme, Israel;
  • Jeff Dachis, OneDrop, USA;
  • Shantanu Gaur, MD, Allurion, USA;
  • Matt Loper, Wellth, USA;
  • Charles O’Connell, FitScript, USA;
  • Scott Smith, Socrates, USA;
  • Anna Sjoberg, Anna PS, Sweden;
  • John Sjolund, Patients Pending Ltd, UK;
  • David Weingard, Fit4D, USA.

We are very proud of all who participated! Every one of them is truly doing magnificent work in advancing the management and care of diabetes.

Once again, congratulations Brianna! We are looking forward to the growth and success of Find Your Ditto!

Patient Entrepreneurs – Lyfebulb’s Rock stars

fullsizerender

When I founded Lyfebulb together with Riccardo Braglia, Helsinn Group Vice Chairman and CEO and Steve Squinto, PhD, co-founder of Alexion and Venture Partner at Orbimed in 2014, it was with the broad goal to address the gaps I had experienced during my personal journey with diabetes and as a business woman and medical scientist.

Above all, I wanted to showcase individuals, who like myself, were not accepting of the role of a passive patient, but willing to take on the challenge of changing the future for themselves and others living with chronic disease.

At Lyfebulb we call these individuals “patient entrepreneurs” not to be confused with the meaning of patience. These people are anything but patient, but they are living with a chronic disease or closely related to someone with a chronic disease and they are not just sitting back waiting for solutions, but they are out there creating products and solutions that may help them and others in the near term.

My goal for Lyfebulb is to create a global organization that is patient-centric and functions as the voice for a larger population of patients, who have until this point been vulnerable and receptive rather than strong and proactive. We feel that it is patients’ responsibility and opportunity to be innovators, teachers and influencers.

This is why the Lyfebulb Entrepreneur Circle is so important. Here we feature people who have made their disease their career. They identify an issue in their lives with the disease and then they address that issue by creating a product or an entire company. That inspires me and I know it inspires others. If one cannot become an entrepreneur one can mentor others, one can influence large companies and one can advocate for progress.

Recently, Lyfebulb announced a partnership with global leader in diabetes, Novo Nordisk focused on this very effort. Together we will grow the Entrepreneur circle and we have tangible plans for how to showcase and promote them, for the benefit of others living with diabetes and the entire space. Products and solutions originated by someone who lives with the disease daily will be more applicable and better accepted by the peer population.

In the Lyfebulb pulse, we will feature one of our Rock Stars every two weeks – show-casing their personal story and their company/idea.

Our next step is to build an incubator in NYC, where new patient entrepreneurs can enjoy a creative environment with access to early funding, infrastructure for a start-up and help to take the next steps when they are ready to leave the incubator within 2 years.

Interests - Select all that apply